Zalicus is halting development of its experimental non-opoid pain drug Z160 after the drug did not outperform a placebo in two Phase II studies. The drug was under development for treatment of shingles-related chronic back pain as well as back pain related to a neurologic condition. Zalicus said it will turn its attention to the non-opioid painkiller candidate Z944.

Full Story:

Related Summaries